(Q53675998)

17 May 2018

title

Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. (English)

1 reference

17 May 2018

main subject

Neisseria meningitidis

1 reference

1

Gunnstein Norheim

1 reference

17 May 2018

2

Audun Aase

1 reference

17 May 2018

Ernst Arne Høiby

4

E Arne Høiby

1 reference

17 May 2018

Dominique A Caugant

3

Dominique A Caugant

1 reference

17 May 2018

Einar Rosenqvist

9

Einar Rosenqvist

1 reference

17 May 2018

Elisabeth Fritzsønn

5

Elisabeth Fritzsønn

1 reference

17 May 2018

Torill Tangen

6

Torill Tangen

1 reference

17 May 2018

author name string

Paul Kristiansen

7

1 reference

17 May 2018

Ulla Heggelund

8

1 reference

17 May 2018

language of work or name

English

0 references

publication date

14 March 2005

1 reference

17 May 2018

published in

Vaccine

1 reference

17 May 2018

volume

23

1 reference

17 May 2018

issue

29

1 reference

17 May 2018

page(s)

3762-3774

1 reference

17 May 2018

Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

A comparison of the variable antigens expressed by clone IV-1 and subgroup III of Neisseria meningitidis serogroup A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Meningococcal serogroup a avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Epidemic spread and antigenic variability of Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Multiple mechanisms of phase variation of PorA in Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Recent advances in the large scale fermentation of Neisseria meningitidis group B for the production of an outer membrane protein complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Immune response to native NadA from Neisseria meningitidis and its expression in clinical isolates in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Neisserial TonB-dependent outer-membrane proteins: detection, regulation and distribution of three putative candidates identified from the genome sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis are similar to Haemophilus influenzae D-15-Ag and Pasteurella multocida Oma87.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

NadA, a novel vaccine candidate of Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Clonal descent and microevolution of Neisseria meningitidis during 30 years of epidemic spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Omp85, an evolutionarily conserved bacterial protein involved in outer-membrane-protein assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Outbreak of meningococcal disease caused by PorA-deficient meningococci.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

7 January 2021

Heat-modifiable outer membrane proteins of Neisseria meningitidis and their organization within the membrane

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

7 January 2021

Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

7 January 2021

Sequence diversity, predicted two-dimensional protein structure, and epitope mapping of neisserial Opa proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

7 January 2021

A potential role for the major iron-regulated protein expressed by pathogenic Neisseria species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

7 January 2021

Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.021

7 January 2021

10.1016/J.VACCINE.2005.02.021

Identifiers

DOI

1 reference

17 May 2018

1 reference

17 May 2018